News & Research Feed

Peptide Therapy News & Research

Research peptides in metabolic, longevity, and recovery indications.

All Retatrutide Tirzepatide Semaglutide Peptide Therapy FDA Updates Clinical Trials Editorial

PubMed Peptide Therapy

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research

Alhalabi H, Borschel L, Le Foll C, et al. — Journal of pharmaceutical and biomedical analysis

2026-06-15 Read source →

PubMed Peptide Therapy

GLP-1 receptor agonists: The good, the bad, and the ugly-A comprehensive guide for NPs

Rodriguez ME, Lavell J, Foreman RM — The Nurse practitioner

2026-05-01 Read source →

PubMed Peptide Therapy

Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions

Patil R, Dunn W, Noureddin M, et al. — Drugs

2026-05-01 Read source →

PubMed Peptide Therapy

Divergent renal benefits of SGLT2 inhibitors and mineralocorticoid receptor antagonists in non-diabetic kidney disease

Chen R, Zhang J, Chen J, et al. — Kidney & blood pressure research

2026-04-24 Read source →

PubMed Peptide Therapy

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study

Remala S, Liang L, Shah AM, et al. — Circulation. Genomic and precision medicine

2026-04-24 Read source →

PubMed Peptide Therapy

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Neves JS, Leite AR, Vasques-Nóvoa F, et al. — Diabetes, obesity & metabolism

2026-04-24 Read source →

PubMed Peptide Therapy

GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes

Mao X, Fan H, Yuen MF, et al. — Hepatology (Baltimore, Md.)

2026-04-23 Read source →

PubMed Peptide Therapy

Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes

Teke E, Öztürk S, Ulutaş ME, et al. — Obesity surgery

2026-04-23 Read source →

PubMed Peptide Therapy

Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure

Fioretti F, Petrie MC, Dickert NW, et al. — Journal of the American College of Cardiology

2026-04-21 Read source →

PubMed Peptide Therapy

The critical role of gut-brain signalling in eating behaviour and obesity

de Lartigue G, Brierley DI, Choi HJ — Nature reviews. Gastroenterology & hepatology

2026-04-21 Read source →

PubMed Peptide Therapy

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial

Liu H, Zhang Y, Feng L, et al. — Nature communications

2026-04-21 Read source →

PubMed Peptide Therapy

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

Yamauchi T, Becker NP, Hagemann CA, et al. — The lancet. Diabetes & endocrinology

2026-04-17 Read source →

PubMed Peptide Therapy

The complexity of malnutrition in people living with excess body weight

Mwala NN, de van der Schueren MAE — Current opinion in clinical nutrition and metabolic care

2026-04-15 Read source →

PubMed Peptide Therapy

Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro

Old V, Davies M, Denniff M, et al. — Journal of cachexia, sarcopenia and muscle

2026-04-01 Read source →

PubMed Peptide Therapy

A review of survodutide: a new dual acting agonist

Yathindra MR, Bhattacharjee A, Pundir N, et al. — Minerva endocrinology

2026-03-19 Read source →

PubMed Peptide Therapy

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression

Ahmed M, Hassan M, Tahir M, et al. — Diabetes, obesity & metabolism

2026-03-16 Read source →

PubMed Peptide Therapy

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

Bailey CJ, Flatt PR, Conlon JM — Peptides

2026-03-01 Read source →

PubMed Peptide Therapy

Bariatric Surgery in the Era of GLP1RA: A Narrative Review

Muhundan M, Dash S — Advances in therapy

2026-03-01 Read source →

PubMed Peptide Therapy

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation

Zimmermann T, Bleymehl K, Haebel P, et al. — Molecular metabolism

2026-03-01 Read source →

PubMed Peptide Therapy

Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study

Wang B, Huang J, Chen Z — Diabetes, obesity & metabolism

2026-03-01 Read source →

PubMed Peptide Therapy

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice

Long F, Challa TD, Efthymiou V, et al. — Diabetes, obesity & metabolism

2026-03-01 Read source →

PubMed Peptide Therapy

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment

Gadelmawla AF, Hammad N, Atta K, et al. — The American journal of cardiology

2026-02-26 Read source →

PubMed Peptide Therapy

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation

Rubino DM, Mooney V, van de Walle V, et al. — Contemporary clinical trials communications

2026-02-01 Read source →

PubMed Peptide Therapy

Strengths and limitations of HFpEF probability scores in the era of precision medicine

Wilk M, Kotwica T, Zymliński R, et al. — Frontiers in medicine

2026-01-01 Read source →

PubMed Peptide Therapy

Genetic architecture of obesity and advances in precision pharmacotherapy: a comprehensive review

Kavaja F, Liehr T, Temaj G — Acta biochimica Polonica

2026-01-01 Read source →

PubMed Peptide Therapy

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes

Elmendorf AJ, Yousefian M, Kim IM, et al. — Pharmacological research

2026-01-01 Read source →

PubMed Peptide Therapy

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials

Andonie CR, Abusalameh A, Ismail I, et al. — Endocrinology, diabetes & metabolism

2026-01-01 Read source →

Sources & methodology. Items aggregated from public scientific and regulatory sources: PubMed (NCBI E-utilities), FDA press releases, and ClinicalTrials.gov v2 API. Summaries are factual excerpts from source records — no editorial commentary. Inclusion does not imply endorsement, and items are not medical advice. Last regenerated: 2026-04-26.